Genmab — April 2016
-
-
wauw - check lige IMGN her i åbningen!
-
og store prygl til GILD som forventet
-
ImmunoGen Reports Wider Q3 Loss Vs. Street, Misses on Revenue; Lowers FY16 Revenue Outlook Below Forecasts<IMGN.OQ> - MT Newswires
29-Apr-2016 13:15:18
07:09 AM EDT, 04/29/2016 (MT Newswires) -- ImmunoGen (IMGN) reported Friday that
for Q3 ended March 31, its loss was wider than expected, and revenue fell short
of analysts' estimates; it also lowered its revenue guidance for fiscal 2016
below Street forecasts.The clinical-stage biotechnology company posted Q3 net loss of $31.9 million, or
$0 -
det kan vist ikke betale sig at skuffe forventninger i det her marked....
-
IMGN justerede guidance - 2016 guidance for its net loss is now expected to be between $135 million and $140 million, versus previous estimate of $120 million and $125 million
-
så ikke noget med klinikken
-
hold da helt kæft, hvor er US sur!
-
kan det anbefales at købe genmab aktier nu?
-
hmm - US minder mest om en basejumper, der har glemt dragten
-
Genmab er stadig det store hit hos Investtec. http://penge.borsen.dk/artikel/1/323780/teknisk_analyse_potentiale_paa_24_pct_i_neutralt_marked.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind